Chinese Journal of Antituberculosis ›› 2013, Vol. 35 ›› Issue (4): 282-285.
Previous Articles Next Articles
Received:
2012-11-26
Online:
2013-04-10
Published:
2013-07-02
[1] Rowland R, McShane H. Tuberculosis vaccines in clinical trials. Expert Rev Vaccines,2011,10(5):645-658.[2] 尹文东,于庭,梁艳,等.结核分枝杆菌重组Ag85A、Ag85B蛋白免疫原性的研究.中国实验诊断学,2011,15(10):1618-1621.[3] Lu D, Garcia-Contreras L, Muttil P,et al. Pulmonary immunization using antigen 85-B polymeric microparticles to boost tuberculosis immunity.AAPS J, 2010,12(3):338-347.[4] Giri PK, Verma I, Khuller GK. Adjunct immunotherapy with Ag85 complex proteins based subunit vaccine in a murine model of Mycobacterium tuberculosis infection. Immunotherapy, 2009,1(1):31-37.[5] 黎友伦,罗永艾,王国治.细胞因子及其受体在结核免疫中的作用.国外医学内科学分册,2005,32(4):146-149.[6] 师长宏,范雄林,柏银兰,等.结核分枝杆菌Ag85B-ESAT6 融合蛋白在小鼠体内诱导的免疫应答及其保护力.第四军医大学学报,2004,25 (18):1633-1636. [7] Langermans JA, Doherty TM, Vervenne RA,et al.Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6.Vaccine,2005,23(21):2740-2750.[8] McShane H, Pathan AA, Sander CR, et al.Recombinant mo-dified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.Nat Med,2004,10(11):1240-1244.[9] Scriba TJ, Tameris M, Mansoor N, et al.Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells.Eur J Immunol,2010,40(1):279-290.[10] Aeras, University of Oxford,European, Developing Countries Clinical Trials Partnership (EDCTP). Protective efficacy against tuberculosis (TB) disease, safety, and immunogenicity of MVA85A/AERAS-485 in HIV-infected adults[EB/OL].[2012-11-25].http://clinicaltrials.gov/ct2/show/NCT01151189?term=MVA+85A&rank=2.htm. [11] van Dissel JT, Soonawala D, Joosten SA, et al.Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection.Vaccine,2011,3(29):2100-2109. [12] Aeras, Crucell Holland BV. Safety and immunogenicity of AERAS-402 in HIV-infected, Bacillus Calmerre-Guerin(BCG)-vaccinated adults[EB/OL].[2012-11-15].http://clinicaltrials.gov/ct2/show/NCT01017536?term=AERAS-402&rank=2.htm. [13] Horwitz MA, Harth G. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis.Infect Immun,2003,71(4):1672-1679.[14] Hoft DF, Blazevic A, Abate G, et al. A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J Infect Dis,2008,198(10):1491-1501.[15] Sugawara I, Sun L, Mizuno S, et al. Protective efficacy of recombinant BCG Tokyo (Ag85A) in rhesus monkeys (Macaca mulatta) infected intratracheally with H37Rv Mycobacterium tuberculosis. Tuberculosis (Edinb),2009,89(1):62-67. [16] Jain R, Dey B, Dhar N, et al.Enhanced and enduring protection against tuberculosis by recombinant BCG-Ag85C and its association with modulation of cytokine profile in lung.PLoS One,2008,3(12):e3869.[17] Xu Y, Liu W, Shen H, et al.Recombinant Mycobacterium bovis BCG expressing the chimeric protein of antigen 85B and ESAT-6 enhances the Th1 cell-mediated response.Clin Vaccine Immunol,2009,16(8):1121-1126.[18] 王平,王丽梅,张薇,等.结核分枝杆菌Ag85B-ESAT-6融合蛋白重组耻垢分枝杆菌对小鼠的免疫原性研究.中国防痨杂志,2012,34(3):145-149.[19] 张灵霞,吴雪琼,董恩军.四种卡介苗重组疫苗对结核病的预防作用.实用医学杂志,2011,27(12):2115-2117.[20] Chang-hong S, Xiao-wu W, Hai Z, et al.Immune responses and protective efficacy of the gene vaccine expressing Ag85B and ESAT6 fusion protein from Mycobacterium tuberculosis.DNA Cell Biol,2008,27(4):199-207.[21] Fan X, Gao Q, Fu R.Differential immunogenicity and protective efficacy of DNA vaccines expressing proteins of Mycobacterium tuberculosis in a mouse model. Microbiol Res,2009,164(4):374-382.[22] 吴雪琼,李洪敏,史迎昌,等.结核分枝杆菌DNA疫苗抗结核作用的研究.中国生物制品学杂志,2002,1(6):340-345.[23] Liang Y, Wu X, Zhang J, et al.The treatment of mice infected with multi-drug-resistant Mycobacterium tuberculosis using DNA vaccines or in combination with rifampin.Vaccine, 2008,26(35):4536-4540.[24] Liang Y,Wu X,Zhang J,et al.Treatment of multi-drug-resis-tant tuberculosis in mice with DNA vaccines alone or incombination in mice chemotherapeutic drugs.Scand J Immunol,2011,74(1):42-46.[25] 梁艳,吴雪琼,张俊仙,等.结核分枝杆菌Ag85A/ESAT-6嵌合型质粒DNA疫苗和抗结核药物联合治疗小鼠耐药结核病的效果研究.中国防痨杂志,2007,29(5):382-385.[26] 胡静,吴雪琼,王丽华,等.结核分支杆菌Ag85B DNA疫苗构建、免疫原性及其保护效力.科学技术与工程,2006,6(13):1765-1770.[27] Tanghe A, D’Souza S, Rosseels V, et al. Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting. Infect Immun,2001,69(5):3041-3047. |
[1] | JIN Hong-jian. The construction of tuberculosis prevention and control service system at county level in China needs to be strengthened urgently —— Comments and suggestions of an old tuberculosis control and prevention worker [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 896-902. |
[2] | ZHU Li-mei, CHEN Can-can, CHEN Wei, HU Xiao-guang, ZHANG Ya-nan, MA Jun-yang. To formulate prevention and control strategy for latent tuberculosis infection population in China [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 794-798. |
[3] | ZHANG Kai, SHEN Xiao-bing, TAO Li-feng, WEI Fen, CHEN Bao-wen, QIU Jing-jing, CHEN Wei, LU Jin-biao, ZHU Yin-meng, CHENG Xing, ZHONG Zai-xin, ZHAO Ai-Hua, PU Jiang. Establishment of quality standards for recombinant Mycobacterium tuberculosis fusion protein [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 814-820. |
[4] | ZHAO Ai-hua, KANG Wan-li, WANG Guo-zhi, GAO Zheng-lun, DU Wei-xin, LU Jin-biao, SHEN Xiao-bing, SU Cheng, XU Miao, ZHENG Su-hua. Screening for latent tuberculosis infection and identification of BCG vaccination by recombinant Mycobacterium tuberculosis 11 kDa [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 821-825. |
[5] | YANG Lu-qi, SHEN Ming-yi, SHA Wei, CHEN Ying-ying, WANG Ying. Research progress in immunoprotective mechanism of bacille Calmette-Guérin and vaccine development strategies [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 863-868. |
[6] | CHEN Ning, SUN Lin, SHEN A-dong, HE Qiu-shui. Possible causes of infection after BCG vaccination [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 869-873. |
[7] | SHEN Xin, SHA Wei, LIU Jian-jun. Impact of coronavirus disease 2019 (COVID-19) on tuberculosis control and countermeasures in China [J]. Chinese Journal of Antituberculosis, 2020, 42(6): 544-548. |
[8] | ZHANG Pei-ze, FU Liang, TAN Jie, WANG Yu-xiang, CHEN Tao, DENG Guo-fang. CT imaging characteristics of cured multidrug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(6): 558-562. |
[9] | LI Jin,GUO Xiao-qin,LI Yong,ZOU Jin-yan,LU Li-ping. Analysis on the effect of active screening of tuberculosis among local people aged 65 or older in Songjiang District of Shanghai in 2018 [J]. Chinese Journal of Antituberculosis, 2020, 42(4): 353-359. |
[10] | GAO Qian,MEI Jian. Reflections on the prevention and control of tuberculosis among Chinese students [J]. Chinese Journal of Antituberculosis, 2020, 42(3): 195-199. |
[11] | SUN Ming-lei, GUAN Li, ZHAO Juan, WANG Chen, ZOU Dan-dan, LIANG Li-bo. Legislative considerations on traffic travel of MDR-TB/XDR-TB patients from the perspective of infectious disease prevention and control [J]. Chinese Journal of Antituberculosis, 2020, 42(12): 1268-1271. |
[12] | CHEN Ning, SUN Lin, SHEN A-dong, HE Qiu-shui. Research progress on the non-specific protective effect of BCG [J]. Chinese Journal of Antituberculosis, 2020, 42(10): 1128-1133. |
[13] | Xiao-ying JIANG,Shi-wen JIANG,Meng-qiu GAO,Wen ZHANG,Zhi-guo ZHANG,Zhi-dong GAO,Hong ZHANG,Jian DU,Fei-fei NIE,Hui ZHANG,Hong-fei DUAN,Feng-ling MI. Suggestions on infection control of active pulmonary tuberculosis patients treated at home [J]. Chinese Journal of Antituberculosis, 2019, 41(9): 920-925. |
[14] | Qing-qing WU,Li-jun SONG,Lin ZHANG. Clinical application of daily awaking execution scale in tuberculosis patients with mechanical ventilation and sedation [J]. Chinese Journal of Antituberculosis, 2019, 41(8): 863-868. |
[15] | Ling-hai LI,Da-qing YU,Chun WANG,Tao LIU,Zhi-guo SHI. Risk factors for development of intraoperative hypothermia in patients undergoing spinal tuberculosis surgery [J]. Chinese Journal of Antituberculosis, 2019, 41(4): 426-429. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||